Jianqin Lu, BPharm, PhD

Assistant Professor, Pharmaceutics and Pharmacokinetics
Director, Pharmaceutics and Pharmacokinetics Track
Assistant Professor, BIO5 Institute
Member, NCI designated UA Comprehensive Cancer Center
Member, Southwest Environmental Health Sciences Center

Jianqin Lu, BPharm, PhD, is an Assistant Professor of Pharmaceutical Sciences in Pharmaceutics and Pharmacokinetics at R. Ken Coit College of Pharmacy (RKCCOP). The Lu research laboratory strives to develop innovative, safe, and efficacious therapeutics at the interface of drug delivery, synthetic chemistry, pharmaceutics, nanotechnology, biomaterials, and tumor immunology to address the pressing unmet needs in current cancer and other diseases therapy and prevention, particularly in the emerging field of combination immunochemotherapy.

Dr. Lu’s research has been published in Nature Nanotechnology, Nature Communications, Biomaterials, etc, and has resulted in a Maximizing Investigators' Research Award (MIRA) (R35) from NIH/NIGMS, an R01 from NIH/NCI, a Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation Research Starter Grant in Drug Delivery, and several pilot and seed grants from the State of Arizona's Technology and Research Initiative Fund (TRIF)/BIO5 Institute and NIH-sponsored The Southwest Environmental Health Sciences Center (SWEHSC).

Recipient of the Norman R. and Priscilla A. Farnsworth Award at the University of Pittsburgh, the NIH/NCI Ruth L. Kirschstein Institutional National Research Service Award (T32) in Tumor Immunology at UCLA, A. Jay Gandolfi New Investigator Award at UArizona, and the 2022 American Association of Colleges of Pharmacy (AACP) Pharmaceutics Research Award. Dr. Lu serves as the Director for Pharmaceutics and Pharmacokinetics Track at RKCCOP, the Associate Editor for Frontiers in Medical Technology: Nano-Based Drug Delivery and was the Secretary of Knowledge Management in AACP Pharmaceutics Section. 


Education & Post Graduate Training: 

Postdoc, Nanomedicine/Tumor Immunology, University of California, Los Angeles, 2019
Postdoc, Nanomedicine, The University of Chicago, Chicago, 2015
PhD, Pharmaceutics, University of Pittsburgh, Pittsburgh, 2014
BS, Pharmacy, Hunan University of Chinese Medicine, Changsha, China, 2010

Areas of Research: 

Drug Delivery
Pharmaceutics and Pharmacokinetics
Cancer Immunotherapy

Types of Research:

Laboratory-based Research
Basic and Applied Sciences
Translational Medicine

Select Publications


Jiang T, Gonzalez KMarie, Cordova LEstrella, Lu J. "Nanotechnology-enabled gene delivery for cancer and other genetic diseases." Expert Opin Drug Deliv. 2023:1-18. PMID: 37017558
Wang Z., Gonzalez K.M., Cordova L.E., Lu J. "Nanotechnology-empowered therapeutics targeting neurodegenerative diseases and aging." WIREs Nanomedicine and Nanobiotechnology . 2023.
Li W, Jiang Y, Lu J. "Nanotechnology-enabled immunogenic cell death for improved cancer immunotherapy." Int J Pharm. 2023;634:122655. PMCID: PMC9975075  PMID: 36720448


Wang Z, Li W, Park J, Gonzalez KMarie, Scott AJames, Lu J. "Camptothesome elicits immunogenic cell death to boost colorectal cancer immune checkpoint blockade." J Control Release. 2022. PMID: 35926754
Li W, Gonzalez KMarie, Chung J, Kim M, Lu J. "Surface-modified nanotherapeutics targeting atherosclerosis." Biomater Sci. 2022. PMID: 35980230
Wang Z, Cordova LEstrella, Chalasani P, Lu J. "Camptothesome Potentiates PD-L1 Immune Checkpoint Blockade for Improved Metastatic Triple-Negative Breast Cancer Immunochemotherapy." Mol Pharm. 2022;19(12):4665-4674. PMID: 36413426


Wang Z, Little N, Chen J, et al. "Immunogenic camptothesome nanovesicles comprising sphingomyelin-derived camptothecin bilayers for safe and synergistic cancer immunochemotherapy." Nat Nanotechnol. 2021. PMID: 34385682
Li W, Little N, Park J, Foster CAlexander, Chen J, Lu J. "Tumor-Associated Fibroblast-Targeting Nanoparticles for Enhancing Solid Tumor Therapy: Progress and Challenges." Mol Pharm. 2021;18(8):2889-2905. PMID: 34260250


Wang Z, Chen J, Little N, Lu J. "Self-assembling Prodrug Nanotherapeutics for Synergistic Tumor Targeted Drug Delivery." Acta Biomater. 2020. PMCID: PMC7245299  PMID: 32454086


Wang X, Chang CHyun, Jiang J, et al. "The Crystallinity and Aspect Ratio of Cellulose Nanomaterials Determine Their Pro-Inflammatory and Immune Adjuvant Effects In Vitro and In Vivo." Small. 2019;15(42):e1901642. PMCID: PMC6800804  PMID: 31461215